Malignant Lung Neoplasm
Malignant lung neoplasms most frequently harbor alterations in TP53, KRAS, EGFR, CDKN2A, and STK11 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in malignant lung neoplasm .
There is 1 clinical trial for malignant lung neoplasm, of which 0 are open and 1 is completed or closed. Of the trial that contains malignant lung neoplasm as an inclusion criterion, 1 is no phase specified (0 open).
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.